BiotechTube

AGS-16M8F

Phase 1Completed
0 watching 0 views this week💤 Quiet
33
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Renal Cell Carcinoma

Conditions

Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F

Trial Timeline

Aug 1, 2010 → Nov 1, 2012

NCT ID
NCT01114230

About AGS-16M8F

AGS-16M8F is a phase 1 stage product being developed by Astellas Pharma for Renal Cell Carcinoma. The current trial status is completed. This product is registered under clinical trial identifier NCT01114230. Target conditions include Renal Cell Carcinoma, Pharmacokinetics of AGS-16M8F.

Hype Score Breakdown

Clinical
10
Activity
5
Company
10
Novelty
3
Community
2

Clinical Trials (1)

NCT IDPhaseStatus
NCT01114230Phase 1Completed

Competing Products

20 competing products in Renal Cell Carcinoma

See all competitors
ProductCompanyStageHype Score
MBX 2109 + MBX 2109 + MBX 2109 + MBX 2109MBX BiosciencesPhase 1
28
LY3473329Eli LillyPhase 1
33
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
SPR001Spruce BiosciencesPhase 2
44
Tildacerfont/PlaceboSpruce BiosciencesPhase 2
44
TildacerfontSpruce BiosciencesPhase 2
44
Drotrecogin alfa activated (Xigris)Eli LillyPhase 2
52
LY3819469Eli LillyPhase 1
33
Atezolizumab + CabozantinibChugai PharmaceuticalPhase 3
77
DS-6000a + DS-6000aDaiichi SankyoPhase 1
33
DS-1093aDaiichi SankyoPhase 1
33
CS-3150Daiichi SankyoPhase 3
77
AGS-16C3FAstellas PharmaPhase 1
33
CP-461Astellas PharmaPhase 2
52
roxadustatAstellas PharmaPhase 3
77
YM178Astellas PharmaPhase 1
33
intravenous immunoglobulins (IVIG)Astellas PharmaPhase 1
33
bixalomerAstellas PharmaPre-clinical
23
ASP8825Astellas PharmaPhase 1
33

Other Products from Astellas Pharma

Tacrolimus, Prograf®Approved
85
micafungin + voriconazoleApproved
85
mirabegron + solifenacinApproved
85
Zolpidem (Myslee®) + placeboApproved
85
TacrolimusApproved
85